Daily Sepsis Research Analysis
Three papers stood out today: a translational study shows that scavenging methylglyoxal with anserine reduces capillary leak and mortality in experimental sepsis; national genomic surveillance from Japan identifies a high-risk MRSA ST764-SCCmecII clone linked to higher 30-day mortality; and mechanistic work reveals CYLD as a key brake on TLR4 signaling in sepsis-induced acute lung injury with therapeutic effects in mice.
Summary
Three papers stood out today: a translational study shows that scavenging methylglyoxal with anserine reduces capillary leak and mortality in experimental sepsis; national genomic surveillance from Japan identifies a high-risk MRSA ST764-SCCmecII clone linked to higher 30-day mortality; and mechanistic work reveals CYLD as a key brake on TLR4 signaling in sepsis-induced acute lung injury with therapeutic effects in mice.
Research Themes
- Endothelial barrier protection and metabolic detoxification in sepsis
- Genomic surveillance linking pathogen evolution to clinical outcomes
- Targeting ubiquitin signaling to modulate innate immunity in sepsis-induced organ injury
Selected Articles
1. Anserine reduces mortality in experimental sepsis by preventing methylglyoxal-induced capillary leakage.
Using human observational data and mechanistic models, the study shows methylglyoxal drives endothelial barrier failure and early mortality in sepsis, and that the dipeptide anserine reverses these effects. Anserine reduced capillary leak and improved survival in vivo through RAGE–MAPK pathway modulation and suppression of junctional disruption.
Impact: This work provides causal evidence linking a metabolic toxin to vascular leak in sepsis and identifies a readily translatable scavenger (anserine) with survival benefit in vivo.
Clinical Implications: Methylglyoxal could be adopted for early risk stratification, and anserine merits early-phase clinical trials as an adjunct to reduce capillary leak and vasopressor/fluid requirements in septic shock.
Key Findings
- Methylglyoxal independently associated with higher 48-hour mortality and increased catecholamine/fluid needs after sepsis onset.
- Carbonyl stress disrupted endothelial junctional proteins via RAGE–MAPK signaling, producing capillary leak.
- Anserine reduced AGE formation, preserved junctional complexes in vitro, and decreased capillary leak and mortality in vivo.
Methodological Strengths
- Translational design integrating human observational analyses with multiple in vivo sepsis models and in vitro mechanistic assays.
- Multi-modal readouts (TEER, cytokines, gene expression, enzyme activity, immunostaining) and pathway dissection (RAGE–MAPK).
Limitations
- Preclinical efficacy; no randomized clinical trial yet to confirm benefit in humans.
- Exact dosing, timing, and safety profile of anserine in septic patients remain to be established.
Future Directions: Prospective trials testing methylglyoxal-guided risk stratification and phase I/II studies of anserine in septic shock with endothelial leak endpoints.
BACKGROUND: We previously identified methylglyoxal as a biomarker for early identification and outcome prediction in human sepsis. We hypothesised that methylglyoxal causally impacts disease severity, and the methylglyoxal-scavenging dipeptide anserine can attenuate the detrimental effects of methylglyoxal. METHODS: Using a translational approach, secondary analyses of two observational trials were performed to test the initial hypotheses. Afterwards, these results were re-evaluated in different murine models of experimental sepsis in vivo. The detrimental effects of methylglyoxal as well as the underlying mechanisms were further assessed in vitro using transendothelial electrical resistance measurements, fluorescence-activated cell sorting analyses, cytokine assays, gene expression analyses, and enzyme activity assays, as well as immunofluorescence and immunohistochemistry staining. FINDINGS: The secondary analyses confirmed methylglyoxal as an independent marker associated with increased mortality within the first 48 h after sepsis onset and high catecholamine and fluid requirements in the first 24 h after sepsis onset. In the sepsis models, methylglyoxal-derived carbonyl stress significantly contributed to the development of capillary leakage by disrupting endothelial barrier-forming proteins. Mechanistically, a pathway involving the receptor of advanced glycation end products and mitogen-activated protein kinase was identified. The methylglyoxal-scavenging dipeptide anserine (β-alanyl-N-methylhistidine) reduced methylglyoxal-induced advanced glycation end-product formation and disruptions of junctional complexes in vitro. Moreover, anserine reduced capillary leakage and mortality in vivo. INTERPRETATION: Methylglyoxal causally contributes to capillary leak formation and mortality in experimental sepsis, which can be mitigated by anserine. Therefore, anserine represents an innovative therapeutic option for the treatment of septic shock. FUNDING: German Research Foundation (grant number BR 4144/2-1).
2. Staphylococcus aureus ST764-SCCmecII high-risk clone in bloodstream infections revealed through national genomic surveillance integrating clinical data.
National genomic surveillance integrating clinical outcomes identified MRSA ST764-SCCmecII as a high-risk bloodstream clone with the highest 30-day mortality in Japan. Phage-mediated acquisition of superantigen toxins and resistance elements drove its divergence from the New York/Japan clone circa 1994.
Impact: Links pathogen genomics to patient mortality at national scale, enabling risk-aware infection control and empiric therapy strategies.
Clinical Implications: Hospitals should consider genomic surveillance to detect high-risk MRSA lineages; recognizing ST764-SCCmecII may inform empiric MRSA coverage, isolation policies, and resource allocation.
Key Findings
- Among 580 bloodstream S. aureus isolates (2019–2020), MRSA ST764-SCCmecII showed the highest 30-day in-hospital mortality.
- ST764-SCCmecII diverged from the ST5-SCCmecII New York/Japan clone, acquiring superantigen toxin phages and resistance genes via mobile elements since around 1994.
- Integrated genomic-clinical surveillance across Japan mapped clonal distribution between eastern and western regions and highlighted three dominant clonal complexes.
Methodological Strengths
- National-scale dataset with whole-genome sequencing, standardized AST, and linked clinical metadata.
- Historical comparative genomics to infer evolutionary trajectory and emergence timing.
Limitations
- Observational design limits causal inference; potential sampling bias and generalizability beyond Japan.
- Clinical management implications (e.g., empiric therapy changes) were not prospectively tested.
Future Directions: Implement prospective genomic-informed stewardship to test whether recognizing high-risk MRSA lineages reduces mortality and transmission.
Antimicrobial resistance is a global health concern, and methicillin-resistant Staphylococcus aureus (MRSA) is one of the highest-priority organisms exhibiting this phenotype. Here, we performed a national surveillance integrating patient clinical data of S. aureus isolated from bloodstream infections. We performed genome sequencing, standardized antimicrobial susceptibility testing, and collected clinical metadata of 580 S. aureus isolates collected during 2019-2020. We focused on three predominant clonal complexes (CC1, CC5, and CC8) and assesses their microbiological and clinical significance, as well as their distribution across eastern and western Japan. Furthermore, we conducted a genomic comparison of the isolates of 2019-2000 with those of 1994-2000 and investigated the evolutionary trajectory of emerging clones from the three dominant clonal complexes. We revealed that the emerging MRSA ST764-SCCmecII showed the highest mortality rate within 30 days of hospitalization. This high-risk clone diverged from the New York/Japan clone (ST5-SCCmecII), which was inferred to have undergone repeated infections with phages carrying superantigen toxin genes and acquired antimicrobial resistance genes via mobile genetic elements, leading to its emergence around 1994. Overall, we provide a blueprint for a national genomic surveillance study that integrates clinical data and enables the identification and evolutionary characterization of a high-risk clone.
3. CYLD links the TRAF6/sNASP axis to TLR4 signaling in sepsis-induced acute lung injury.
CYLD binds sNASP to restrain TRAF6 activation in TLR4 signaling; phosphorylation-dependent release of CYLD permits cytokine production, while PP4-driven dephosphorylation reforms the inhibitory complex. Adenoviral CYLD expression attenuated CLP-induced lung injury and cytokines, nominating CYLD as a therapeutic target in sepsis-induced ALI.
Impact: Elucidates a phosphorylation- and ubiquitination-dependent checkpoint linking sNASP, TRAF6, and TLR4 in sepsis lung injury, with in vivo therapeutic proof-of-concept.
Clinical Implications: Modulating CYLD or its interactions within the TRAF6/sNASP/PP4 axis could dampen hyperinflammation in sepsis-induced lung injury; drug discovery for CYLD activators or stabilizers is warranted.
Key Findings
- CYLD directly binds sNASP to prevent TRAF6 activation; TLR4-driven sNASP phosphorylation releases CYLD, enabling TRAF6 autoubiquitination and cytokine production.
- PP4-mediated dephosphorylation of sNASP reforms the sNASP–TRAF6–CYLD inhibitory complex.
- Adenoviral CYLD expression reduced CLP-mediated lung injury and IL-6/TNF-α production in mice; sNASP knockdown abrogated CYLD’s inhibitory effects.
Methodological Strengths
- Mechanistic dissection with protein–protein interaction mapping and phosphorylation-dependent regulation.
- In vivo validation using CLP sepsis model and adenoviral gene delivery demonstrating functional rescue.
Limitations
- Preclinical mouse study without human validation; gene therapy approach may not translate directly.
- Potential off-target effects of adenoviral overexpression were not fully explored.
Future Directions: Identify small-molecule modulators of CYLD–sNASP–TRAF6 interactions and validate CYLD pathway biomarkers in patients with sepsis-induced lung injury.
Sepsis-induced acute lung injury (ALI) involves severe lung dysfunction and leads to high morbidity and mortality rates due to the lack of effective treatments. The somatic nuclear autoantigenic sperm protein (sNASP)/tumor necrosis factor receptor-associated factor 6 (TRAF6) axis plays a crucial role in regulating inflammatory responses during sepsis through Toll-like receptor 4 (TLR4) signaling. However, it is unclear whether deubiquitinating enzymes affect the TRAF6/sNASP axis. In this study, we showed that cylindromatosis (CYLD) directly binds to the sNASP and prevents TRAF6 activation. When TLR4 is activated, phosphorylation of sNASP releases CYLD from the TRAF6/sNASP complex, leading to TRAF6 autoubiquitination and the production of proinflammatory cytokines. To stop TRAF6 activation, a complex of sNASP, TRAF6, and CYLD is reformed once dephosphorylation of sNASP occurs by protein phosphatase 4 (PP4). Silencing sNASP negated the inhibitory effects of CYLD on interleukin (IL)-6 and TNF-α production after lipopolysaccharide (LPS) treatment. Similarly, the absence of CYLD also reduced PP4's negatively regulated production of proinflammatory cytokines, indicating that phosphorylation is crucial for the interaction between sNASP and CYLD as well as TRAF6 activation. Finally, mice infected with a recombinant adenovirus carrying the CYLD gene (Ad-CYLD WT), but not a mutation, showed significant reductions in cecal ligation and puncture (CLP)-mediated lung injury and proinflammatory cytokine production. In conclusion, CYLD alleviated sepsis-induced inflammation by interacting with the TRAF6/sNASP axis. These findings suggest that CYLD could be a potential therapeutic target for treating sepsis-induced ALI.